Alpha Cognition Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for Alzheimer's disease and amyotrophic lateral sclerosis (ALS). It develops ALPHA-1062, an acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer's type and mild traumatic brain injury; and ALPHA-0602, a gene therapy for the treatment of ALS. The company was formerly known as Crystal Bridge Enterprises Inc. and changed its name to Alpha Cognition Inc. in March 2021. Alpha Cognition Inc. was founded in 2000 and is headquartered in Vancouver, Canada.

Alpha Cognition Inc.

Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein.  It is in preclinical development for the treatment of ALS.  ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.

	Jul '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue					86.03K -
gross profit					-86.03K -
selling and marketing expenses			103.25K -	31.73K 69.27%
general and administrative expenses		950.71K -	3.40M 257.86%	4.53M 33.03%
selling general and administrative expenses	98.70K -	950.71K 863.22%	3.51M 268.72%	4.56M 30.02%	4.88M 7.15%
research and development expenses		4.67M -	7.97M 70.62%	8.82M 10.58%	5.09M 42.27%
other expenses			-1.40M -
cost and expenses	98.70K -	5.71M 5,680.21%	11.57M 102.78%	13.47M 16.40%	10.06M 25.30%
operating expenses	98.70K -	5.71M 5,680.21%	11.57M 102.78%	13.47M 16.40%	9.97M 25.93%
interest expense		770.37K -	528.16K 31.44%	172.88K 67.27%	68.95K 60.12%
ebitda	-98.70K -	-5.60M 5,574.86%	-11.48M 104.90%	-13.37M 16.52%	-9.97M 25.42%
operating income	-98.70K -	-5.68M 5,657.38%	-11.57M 103.55%	-13.46M 16.40%	-10.06M 25.28%
depreciation and amortization		81.44K -	89.88K 10.35%	90.92K 1.16%	86.03K 5.38%
total other income expenses net		668.75K -	-7.45M 1,214.04%	1.52M 120.43%	-3.97M 360.58%
income before tax	-90.57K -	-5.78M 6,286.45%	-19.55M 237.90%	-12.11M 38.02%	-14.03M 15.77%
income tax expense		770.37K -	528.16K 31.44%	172.88K 67.27%	1 100.00%
net income	-90.57K -	-5.78M 6,286.45%	-19.55M 237.90%	-12.11M 38.02%	-14.03M 15.77%
weighted average shs out	822.58K -	51.84M 6,202.62%	53.33M 2.87%	67.97M 27.45%	94.36M 38.81%
weighted average shs out dil	822.58K -	51.84M 6,202.62%	53.33M 2.87%	67.97M 27.45%	94.36M 38.81%
eps	-0.11 -	-0.11 0%	-0.37 236.36%	-0.18 51.35%	-0.15 16.67%
epsdiluted	-0.11 -	-0.11 0%	-0.37 236.36%	-0.18 51.35%	-0.15 16.67%

COM:ALPHACOGNITION

Alpha Cognition Inc.

Market Cap

85.20M

Beta: -

Volume Today

88.53K

Avg: -

Preview